Results 201 to 210 of about 22,824 (329)

Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents

Luis E.B. Bettio, Girish Bankar, Céline Dubé, Karen Nelkenbrecher, Maja Filipovic, Sarbjot Singh, Glenn E. DeBoer, Stephanie J. Lee, Andrea Lindgren, Luis Sojo, Richard Dean, J. P. Johnson, Nina Weishaupt   +12 more
openalex   +2 more sources

Clioquinol as a new therapy in epilepsy: From preclinical evidence to a proof‐of‐concept clinical study

Epilepsia, EarlyView.
Abstract Objective Drug‐resistant epilepsy (DRE) affects >25 million people worldwide and is often associated with neuroinflammation. Increasing evidence links deficiency or malfunctioning of the enzyme phosphoglycerate dehydrogenase (PHGDH), which converts 3‐phosphoglycerate to generate serine and the neurotransmitter glycine, with (drug‐resistant ...
Karin Thevissen, Annelii Ny, Daniëlle Copmans, Jana Tits, Kenichi Kamata, Eva Gielis, Kevin Longin, Jo Sourbron, Peravina Thergarajan, Tracie Huey‐Lin Tan, Idrish Ali, Nigel C. Jones, Terence J. O'Brien, Mastura Monif, Bridgette D. Semple, Christine Germeys, Benedetta Frizzi, Virginia Minniti, Sebastian Perrone, Carole L. Linster, Ilaria Elia, Ludo Van Den Bosch, Bruno P. A. Cammue, Arnout Voet, Lieven Lagae, Peter de Witte   +25 more
wiley   +1 more source

Subchronic Treatment with CBZ Transiently Attenuates Its Anticonvulsant Activity in the Maximal Electroshock-Induced Seizure Test in Mice. [PDF]

Int J Mol Sci
Banach M, Borowicz KK.
europepmc   +1 more source

Enantioselective comparative analysis of the anticonvulsant potency of fenfluramine and norfenfluramine in mice

Epilepsia, EarlyView.
Abstract Objective The in vivo effects of fenfluramine result from the combined actions of four active molecular entities (l‐fenfluramine, d‐fenfluramine, and the corresponding enantiomers of the primary metabolite norfenfluramine). Each of these compounds has different properties, with cardiovascular toxicity risk being ascribed primarily to the d ...
Yara Sheeni, Natalia Erenburg, Dinorah Barasch, Tawfeeq Shekh‐Ahmad, Emilio Perucca, Meir Bialer   +5 more
wiley   +1 more source

A NEW APPROACH TO THE USE OF ELECTROSHOCK DEVICES IN COMBATING VENTRICULAR FIBRILLATION [PDF]

, 1955
Seymour Schotz, EDWARD L. BIRKMIRE
openalex   +1 more source

Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models

Epilepsia, 2009
M. M. Blanco, Jair Guilherme Dos Santos Jr, P. Perez‐Mendes, S. R. B. Kohek, C. Cavarsan, M. Hummel, Cristóvão Albuquerque, L. Mello   +7 more
semanticscholar   +1 more source

Electrical stimulation of stem cell–derived human neural networks for evaluating anti‐seizure medications

Epilepsia, EarlyView.
Abstract Objective Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable
Joshua Nicholls, Jinchao Gu, Zhibin Chen, Zikou Liu, Ana Antonic‐Baker, Muhammad Shahid Javaid, Eliza Moore, Hailin Zhu, Afaf Altalhi, David K. Wright, Huseyin Sumer, Terence J. O'Brien, Patrick Kwan, Ben Rollo   +13 more
wiley   +1 more source

Disruption of adenosine metabolism increases risk of seizure-induced death despite decreased seizure severity. [PDF]

Epilepsia
Purnell B, Bhasin J, Rust B, George S, Bah K, Lu T, Fedele D, Boison D.   +7 more
europepmc   +1 more source

Changes in the permeability of fluorescein isothiocyanate dextrans to the blood-brain barrier by electroshock and carbon dioxide inhalation in mice

, 1986
Takeshi Koja, Chikara Kishita, Takao Shimizu, Kanji Izumi, Takeo Fukuda   +4 more
openalex   +1 more source

Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies

Epilepsia, EarlyView.
Abstract Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease‐targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second‐generation drug candidates ...
Heidrun Potschka, Daniel Pérez‐Pérez
wiley   +1 more source